16
Jul
Azafaros press release: Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C
We are pleased to share the latest press release from Azafaros related
Read more
25
Apr
Sanofi Press Release: Sanofi’s AMETHIST trial for GM2 gangliosidosis discontinued
Today it was announced by Sanofi that the AMETHIST phase 3 study of venglustat
Read more
12
Mar
Azafaros RAINBOW study update: Completion of 12 week phase 2
Azafaros has just announced the successful completion of its 12-week Phase 2
Read more
22
Jan
Patient-Focused Drug Development (PFDD) meeting with the FDA for GM2 Gangliosidosis
Our friends at the National Tay-Sachs & Allied Diseases Association have been
Read more
15
Mar
WORLDSymposium 2021 poster
In February 2021 we were delighted to present our latest poster alongside
Read more
15
Mar
National Organization for Rare Disorders (NORD) Summit 2020 Poster
In October 2020 we were delighted to present alongside our registry partners
Read more
15
Mar
Intrabio IB1001-202 Clinical Trial
The FAQ and clinical trial brochure for the Intrabio IB1001-202 trial can
Read more
15
Mar
NOW Enrolling: GM2 gangliosidosis Gene Therapy Clinical Trial at Queens University
Global enrollment is now open for the TSHA-101 clinical trial at Queens
Read more
21
Oct
IB1001 Ongoing, Multinational Clinical Trials update
IntraBio is currently conducting three clinical trials with its lead compound IB1001 (N-acetyl-L-leucine) across
Read more